Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EO2002 for Corneal Edema
NCT04894110Phase 1Completed
- Sponsor
- Emmetrope Ophthalmics LLC
- Start
- Jun 2021
- Primary completion
- Oct 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of EO2002 in corneal edema, Fuchs endothelial corneal dystrophy (FECD) and bullous keratopathy (PBK) (4 arms), sponsored by Emmetrope Ophthalmics LLC. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 26 weeks. Started Jun 2021; status: completed.
02
Drugs
EO2002
03
Conditions
corneal edemaFuchs endothelial corneal dystrophy (FECD)bullous keratopathy (PBK)
Beyond the preview
Go deeper on NCT04894110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04894110.